Hyderabad Researchers Unveil New Method to Combat Candida albicans

A study from Hyderabad reveals a novel approach to disarm the Candida albicans fungus without killing it.

A
Aapla Nagpur Desk
18 Nov 2026, 6:57 PM IST · 2 min read
Source: Thesouthfirst
Hyderabad Researchers Unveil New Method to Combat Candida albicans
KEY TAKEAWAYS
1

Scientists at CSIR-CCMB have discovered compounds that inhibit Candida albicans' transformation into harmful forms.

2

The research highlights the role of glycolysis in the fungus's morphogenesis and suggests new therapeutic strategies.

3

One compound showed promise in enhancing the effectiveness of existing antifungal treatments.

A groundbreaking study from the CSIR-Centre for Cellular and Molecular Biology (CCMB) in Hyderabad has introduced a novel strategy to combat the common fungus Candida albicans. Led by Dr. Sriram Varahan, the research focuses on disarming the fungus rather than killing it, which could lead to more effective treatment options for infections caused by this pathogen.

Candida albicans is a fungus that resides harmlessly in many individuals but can cause severe infections when it enters the bloodstream or internal organs. Traditionally, antifungal treatments either aim to kill the fungus or inhibit its growth. However, the CCMB research team has identified a new approach that targets the fungus's ability to transform into its harmful, filamentous form, which is resistant to immune responses.

The researchers conducted a systematic screening of small molecules that target glycolysis, the metabolic pathway responsible for sugar processing. They discovered two compounds that effectively inhibited the formation of the long, invasive filaments while allowing the fungus to remain in its less harmful, rounded state. Dr. Varahan emphasized that these compounds could serve as a foundation for further research into disrupting the behaviors associated with fungal infections.

In addition to inhibiting filament formation, the identified compounds also demonstrated the ability to penetrate the protective biofilms formed by Candida albicans, which often shield the fungus from conventional antifungal treatments. One compound notably reduced biofilm formation in laboratory tests and increased the fungus's sensitivity to existing antifungal medications like fluconazole and amphotericin B. This suggests that targeting metabolic pathways could enhance the efficacy of current antifungal therapies.

The study's findings, published in the journal ACS Infectious Diseases, indicate that the lead compound significantly improved survival rates in preclinical mouse models of systemic Candida infection. Dr. Varahan and his team are optimistic that their approach could lead to complementary strategies alongside existing antifungal treatments, potentially revolutionizing how fungal infections are managed in clinical settings.

💬What did you think of this story?What did you think?

Read Next

New Method to Combat Candida albicans in Hyderabad